Skip to main content
Have a personal or library account? Click to login
Di-Chimeric Cell Therapy Derived From Hematopoietic and Mesenchymal Stem Cells Promotes Immune Tolerance and Extends Vascularized Composite Allograft Survival Cover

Di-Chimeric Cell Therapy Derived From Hematopoietic and Mesenchymal Stem Cells Promotes Immune Tolerance and Extends Vascularized Composite Allograft Survival

Open Access
|Apr 2026

Authors

Maria Siemionow

siemiom@uic.edu

Department of Orthopaedics, University of Illinois at Chicago, Chicago, USA

Safak Halil Uygur

Department of Orthopaedics, University of Illinois at Chicago, Chicago, USA

Katarzyna Stawarz

Department of Orthopaedics, University of Illinois at Chicago, Chicago, USA

Lucile Chambily

Department of Orthopaedics, University of Illinois at Chicago, Chicago, USA

Katarzyna Budzynska

Department of Orthopaedics, University of Illinois at Chicago, Chicago, USA

Weronika Radecka

Department of Orthopaedics, University of Illinois at Chicago, Chicago, USA
Language: English
Submitted on: Dec 19, 2025
Accepted on: Feb 23, 2026
Published on: Apr 9, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2026 Maria Siemionow, Safak Halil Uygur, Katarzyna Stawarz, Lucile Chambily, Katarzyna Budzynska, Weronika Radecka, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.